ArticleBMC public health2026
Clinical characteristics, treatment patterns, and prognosis in vulvar cancer and vaginal cancer: a national multicenter retrospective study in China.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVulvar and vaginal cancers significantly impact women’s health and quality of life. This study analyzes the prevalence of human papillomavirus (HPV), clinicopathological characteristics, treatment patterns, and survival outcomes, to understand their relationships and better guide prevention and therapy for Chinese patients with vulvar or vaginal cancer.
methodsWe conducted a retrospective, multicenter study across nine tertiary hospitals located in seven regions of China, including patients diagnosed and treated between 2017 and 2021. Data were collected from medical records and standardized questionnaires, with routine clinical follow-up. Continuous variables were analyzed using the Wilcoxon rank-sum test, while categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. Survival outcomes, including overall survival and disease-free survival, were evaluated using the Kaplan-Meier method and multivariable cox proportional hazards regression.
resultsA total of 218 patients (131 vulvar, 87 vaginal) were analyzed. HPV infection was significantly higher in vaginal than vulvar cancer (76.1% vs. 33.8%, p < 0.001). A non-significant trend toward younger age at diagnosis has been observed in HPV-positive vulvar cancer patients (p = 0.072). Both vulvar and vaginal cancers were predominantly early-stage (FIGO I: 57.3% vs. 51.7%), but vulvar tumors were more often well-differentiated (46.7%), while vaginal cancers were mainly moderately (39.2%) or poorly differentiated (23.5%). Receiving surgery during primary treatment phase was more common in vulvar cancer (84.6% vs. 50.6%, p < 0.001), often without adjuvant therapy (p = 0.016). Primary surgery was associated with longer overall survival and disease-free survival in vulvar cancer (p < 0.001), but not in vaginal cancer. A non-significant trend toward longer disease-free survival was observed in HPV-positive vulvar cancer patients (p = 0.107).
conclusionsVulvar and vaginal cancers exhibit distinct profiles in histological differentiation, HPV prevalence and age association. Surgery is central to vulvar cancer management and correlates with survival benefit, whereas vaginal cancer treatment is more heterogeneous. HPV status may have modest prognostic relevance in vulvar cancer, warranting further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.